Top segments and regional performance

Last year, the company generated ‪247.00 M‬ USD, the most of which — ‪247.00 M‬ USD — came from its top-performing segment, Immunotherapies, compared to ‪258.00 M‬ USD the previous year. The greatest contribution came from United States, which accounted for ‪247.00 M‬ USD last year, with ‪258.00 M‬ USD the year before.